Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Luciano Gastaldo is active.

Publication


Featured researches published by Luciano Gastaldo.


Chemistry & Biology | 2008

Determining the Structure and Mode of Action of Microbisporicin, a Potent Lantibiotic Active Against Multiresistant Pathogens

Franca Castiglione; Ameriga Lazzarini; Lucia Carrano; Emiliana Corti; Ismaela Ciciliato; Luciano Gastaldo; Paolo Candiani; Daniele Losi; Flavia Marinelli; Enrico Selva; Francesco Parenti

Antibiotics blocking bacterial cell wall assembly (beta-lactams and glycopeptides) are facing a challenge from the progressive spread of resistant pathogens. Lantibiotics are promising candidates to alleviate this problem. Microbisporicin, the most potent antibacterial among known comparable lantibiotics, was discovered during a screening applied to uncommon actinomycetes. It is produced by Microbispora sp. as two similarly active and structurally related polypeptides (A1, 2246-Da and A2, 2230-Da) of 24 amino acids linked by 5 intramolecular thioether bridges. Microbisporicin contains two posttranslational modifications that have never been reported previously in lantibiotics: 5-chloro-trypthopan and mono- (in A2) or bis-hydroxylated (in A1) proline. Consistent with screening criteria, microbisporicin selectively blocks peptidoglycan biosynthesis, causing cytoplasmic UDP-linked precursor accumulation. Considering its spectrum of activity and its efficacy in vivo, microbisporicin represents a promising antibiotic to treat emerging infections.


Protein Expression and Purification | 2008

Optimization of glutaryl-7-aminocephalosporanic acid acylase expression in E. coli.

Federica Volontè; Flavia Marinelli; Luciano Gastaldo; Silvia Sacchi; Mirella S. Pilone; Loredano Pollegioni; Gianluca Molla

A recombinant glutaryl-7-aminocephalosporanic acid acylase (GLA) from Pseudomonas N176 has been over-expressed in BL21(DE3)pLysS Escherichia coli cells. By alternating screenings of medium components and simplified factorial experimental designs, an improved microbial process was set up at shake-flask level (and then scaled up to 2L-fermentors) giving a approximately 80- and 120-fold increase in specific and volumetric enzyme productivity, respectively. Under the best expression conditions, approximately 1380 U/g cell and 16,100 U/L of GLA were produced versus the approximately 18 U/g cell and the approximately 140 U/L obtained in the initial standard conditions. Osmotic stress caused by the addition of NaCl, low cell growth rate linked to high biomass yield in the properly-designed rich medium, optimization of the time and the amount of inducers addition and decrease of temperature during recombinant protein production, represent the factors concurring to achieve the reported expression level. Notably, this expression level is significantly higher than any previously described production of GLAs. High volumetric production, cost reduction and the simple one-step chromatographic purification of the His-tagged recombinant enzyme, makes this GLA an economic tool to be used in the 7-ACA industrial production.


Microbial Cell Factories | 2011

Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin

Carlo Taurino; Luca Frattini; Giorgia Letizia Marcone; Luciano Gastaldo; Flavia Marinelli

BackgroundTeicoplanin is a glycopeptide antibiotic used clinically in Europe and in Japan for the treatment of multi-resistant Gram-positive infections. It is produced by fermenting Actinoplanes teichomyceticus. The pharmaceutically active principle is teicoplanin A2, a complex of compounds designated T-A2-1-A2-5 differing in the length and branching of the fatty acid moiety linked to the glucosamine residue on the heptapeptide scaffold. According to European and Japanese Pharmacopoeia, components of the drug must be reproduced in fixed amounts to be authorized for clinical use.ResultsWe report our studies on optimizing the fermentation process to produce teicoplanin A2 in A. teichomyceticus ATCC 31121. Robustness of the process was assessed on scales from a miniaturized deep-well microtiter system to flasks and 3-L bioreactor fermenters. The production of individual factors T-A2-1-A2-5 was modulated by adding suitable precursors to the cultivation medium. Specific production of T-A2-1, characterized by a linear C10:1 acyl moiety, is enhanced by adding methyl linoleate, trilinoleate, and crude oils such as corn and cottonseed oils. Accumulation of T-A2-3, characterized by a linear C10:0 acyl chain, is stimulated by adding methyl oleate, trioleate, and oils such as olive and lard oils. Percentages of T-A2-2, T-A2-4, and, T-A2-5 bearing the iso-C10:0, anteiso-C11:0, and iso-C11:0 acyl moieties, respectively, are significantly increased by adding precursor amino acids L-valine, L-isoleucine, and L-leucine. Along with the stimulatory effect on specific complex components, fatty acid esters, oils, and amino acids (with the exception of L-valine) inhibit total antibiotic productivity overall. By adding industrial oils to medium containing L-valine the total production is comparable, giving unusual complex compositions.ConclusionsSince the cost and the quality of teicoplanin production depend mainly on the fermentation process, we developed a robust and scalable fermentation process by using an industrial medium in which a complex composition can be modulated by the combined addition of suitable precursors. This work was performed in the wild-type strain ATCC 31121, which has a clear genetic background. This is important for starting a rational improvement program and also helps to better control teicoplanin production during process and strain development.


The Journal of Antibiotics | 1991

ANTIBIOTIC GE2270 A: A NOVEL INHIBITOR OF BACTERIAL PROTEIN SYNTHESIS

Enrico Selva; Grazia Beretta; N. Montanini; G. S. Saddler; Luciano Gastaldo; Pietro Ferrari; R. Lorenzetti; P. Landini; Franca Ripamonti; Beth P. Goldstein; Marisa Berti; L. Montanaro; Maurizio Denaro


Biochemistry | 2006

Novel tetrapeptide inhibitors of bacterial protein synthesis produced by a Streptomyces sp.

Letizia Brandi; Ameriga Lazzarini; Linda Cavaletti; Monica Abbondi; Emiliana Corti; Ismaela Ciciliato; Luciano Gastaldo; Alessandra Maria Marazzi; Marina Feroggio; Attilio Fabbretti; Alessandro Maio; Luigi Colombo; Stefano Donadio; Flavia Marinelli; Daniele Losi; Claudio O. Gualerzi; Enrico Selva


The Journal of Antibiotics | 2004

Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. I. Taxonomy, isolation and characterization.

Ismaela Ciciliato; Emiliana Corti; Edoardo Sarubbi; Stefania Stefanelli; Luciano Gastaldo; Nicoletta Montanini; Michael Kurz; Daniele Losi; Flavia Marinelli; Enrico Selva


The Journal of Antibiotics | 2004

Valine Influences Production and Complex Composition of Glycopeptide Antibiotic A40926 in Fermentations of Nonomuraea sp. ATCC 39727

Fabrizio Beltrametti; Srdjan Jovetic; Marina Feroggio; Luciano Gastaldo; Enrico Selva; Flavia Marinelli


The Journal of Antibiotics | 1989

A42867, a novel glycopeptide antibiotic

Ernesto Riva; Luciano Gastaldo; M. G. Beretta; Pietro Ferrari; Luigi Franco Zerilli; Giovanni Cassani; Enrico Selva; Beth P. Goldstein; Marisa Berti; F. Parenti; Maurizio Denaro


Archive | 2005

Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof

Ameriga Lazzarini; Luciano Gastaldo; Gianpaolo Candiani; Ismaela Ciciliato; Daniele Losi; Flavia Marinelli; Enrico Selva; Franco Parenti


Archive | 1985

Antibiotic A 40926 complex and its pure factors PA, PB, A, B and B0

Enrico Selva; Grazia Beretta; Luciano Gastaldo; Angelo Borghi; Beth P. Goldstein; Giovanni Cassani; Vittorio Arioli; Francesco Parenti

Collaboration


Dive into the Luciano Gastaldo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Franco Parenti

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge